94 related articles for article (PubMed ID: 19789371)
1. The safety of H(2)-blockers use during pregnancy.
Matok I; Gorodischer R; Koren G; Sheiner E; Wiznitzer A; Uziel E; Levy A
J Clin Pharmacol; 2010 Jan; 50(1):81-7. PubMed ID: 19789371
[TBL] [Abstract][Full Text] [Related]
2. The safety of metoclopramide use in the first trimester of pregnancy.
Matok I; Gorodischer R; Koren G; Sheiner E; Wiznitzer A; Levy A
N Engl J Med; 2009 Jun; 360(24):2528-35. PubMed ID: 19516033
[TBL] [Abstract][Full Text] [Related]
3. Major malformations following exposure to nonsteroidal antiinflammatory drugs during the first trimester of pregnancy.
Daniel S; Matok I; Gorodischer R; Koren G; Uziel E; Wiznitzer A; Levy A
J Rheumatol; 2012 Nov; 39(11):2163-9. PubMed ID: 22984274
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services.
Garbis H; Elefant E; Diav-Citrin O; Mastroiacovo P; Schaefer C; Vial T; Clementi M; Valti E; McElhatton P; Smorlesi C; Rodriguez EP; Robert-Gnansia E; Merlob P; Peiker G; Pexieder T; Schueler L; Ritvanen A; Mathieu-Nolf M
Reprod Toxicol; 2005; 19(4):453-8. PubMed ID: 15749258
[TBL] [Abstract][Full Text] [Related]
5. Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones.
Wogelius P; Nørgaard M; Gislum M; Pedersen L; Schønheyder HC; Sørensen HT
Int J Antimicrob Agents; 2005 Oct; 26(4):323-6. PubMed ID: 16144758
[TBL] [Abstract][Full Text] [Related]
6. The health consequences of teenage fertility.
Makinson C
Fam Plann Perspect; 1985; 17(3):132-9. PubMed ID: 2431924
[TBL] [Abstract][Full Text] [Related]
7. Safety of first trimester exposure to H2 blockers.
Lagace E
J Fam Pract; 1996 Oct; 43(4):342-3. PubMed ID: 8874364
[No Abstract] [Full Text] [Related]
8. Bias toward the null hypothesis in pregnancy drug studies that do not include data on medical terminations of pregnancy: the folic acid antagonists.
Levy A; Matok I; Gorodischer R; Sherf M; Wiznitzer A; Uziel E; Koren G
J Clin Pharmacol; 2012 Jan; 52(1):78-83. PubMed ID: 21343345
[TBL] [Abstract][Full Text] [Related]
9. Pivmecillinam and adverse birth and neonatal outcomes: a population-based cohort study.
Vinther Skriver M; Nørgaard M; Pedersen L; Carl Schønheyder H; Sørensen HT
Scand J Infect Dis; 2004; 36(10):733-7. PubMed ID: 15513399
[TBL] [Abstract][Full Text] [Related]
10. Risk of perinatal mortality associated with asthma during pregnancy.
Breton MC; Beauchesne MF; Lemière C; Rey E; Forget A; Blais L
Thorax; 2009 Feb; 64(2):101-6. PubMed ID: 19008298
[TBL] [Abstract][Full Text] [Related]
11. Fetal safety of macrolides.
Bahat Dinur A; Koren G; Matok I; Wiznitzer A; Uziel E; Gorodischer R; Levy A
Antimicrob Agents Chemother; 2013 Jul; 57(7):3307-11. PubMed ID: 23650169
[TBL] [Abstract][Full Text] [Related]
12. The safety of calcium channel blockers during pregnancy: a prospective, multicenter, observational study.
Weber-Schoendorfer C; Hannemann D; Meister R; Eléfant E; Cuppers-Maarschalkerweerd B; Arnon J; Vial T; Rodriguez-Pinilla E; Clementi M; Robert-Gnansia E; De Santis M; Malm H; Dolivo A; Schaefer C
Reprod Toxicol; 2008 Sep; 26(1):24-30. PubMed ID: 18585452
[TBL] [Abstract][Full Text] [Related]
13. Maternal use of fluconazole and risk of congenital malformations: a Danish population-based cohort study.
Nørgaard M; Pedersen L; Gislum M; Erichsen R; Søgaard KK; Schønheyder HC; Sørensen HT
J Antimicrob Chemother; 2008 Jul; 62(1):172-6. PubMed ID: 18400803
[TBL] [Abstract][Full Text] [Related]
14. Perinatal effects of amphetamine and heroin use during pregnancy on the mother and infant.
Thaithumyanon P; Limpongsanurak S; Praisuwanna P; Punnahitanon S
J Med Assoc Thai; 2005 Nov; 88(11):1506-13. PubMed ID: 16471094
[TBL] [Abstract][Full Text] [Related]
15. Exposure to nitrofurantoin during the first trimester of pregnancy and the risk for major malformations.
Goldberg O; Koren G; Landau D; Lunenfeld E; Matok I; Levy A
J Clin Pharmacol; 2013 Sep; 53(9):991-5. PubMed ID: 23873250
[TBL] [Abstract][Full Text] [Related]
16. Determinants of low birth weight: a community based prospective cohort study.
Hirve SS; Ganatra BR
Indian Pediatr; 1994 Oct; 31(10):1221-5. PubMed ID: 7875782
[TBL] [Abstract][Full Text] [Related]
17. The safety of fetal exposure to proton-pump inhibitors during pregnancy.
Matok I; Levy A; Wiznitzer A; Uziel E; Koren G; Gorodischer R
Dig Dis Sci; 2012 Mar; 57(3):699-705. PubMed ID: 22038541
[TBL] [Abstract][Full Text] [Related]
18. Outcome of pregnancy after first trimester exposure to H2 receptor antagonists.
Koren G; Zemlickis DM
Am J Perinatol; 1991 Jan; 8(1):37-8. PubMed ID: 1670987
[TBL] [Abstract][Full Text] [Related]
19. The safety of cetirizine during pregnancy. A prospective observational cohort study.
Weber-Schoendorfer C; Schaefer C
Reprod Toxicol; 2008 Sep; 26(1):19-23. PubMed ID: 18571373
[TBL] [Abstract][Full Text] [Related]
20. Antiglaucoma medications during pregnancy and the risk of low birth weight: a population-based study.
Ho JD; Hu CC; Lin HC
Br J Ophthalmol; 2009 Oct; 93(10):1283-6. PubMed ID: 19520696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
